- B2B
- Has physical offices
- Publicly traded
- Manufacturing
- Healthtech
- Sales-led purchase
- Pharma & life sciences
- Multi-site
- International operations
- Has production sites
- Has in-house R&D
- Has field sales reps
- Handles regulated data
About Alnylam Pharmaceuticals
A global biotech company pioneering RNAi therapeutics to treat rare genetic diseases, with a breakthrough product and a robust pipeline
Key facts
- Industry
- Biotechnology Research
- Company size
- 1,001–5,000 employees
- Headquarters
- cambridge, massachusetts, United States
- Founded
- 2002
- Revenue
- €86.1MFY2025, filed accounts, INPI
- SIREN
- 818575730
- Website
- alnylam.com
Who should you contact at Alnylam Pharmaceuticals?
Connect to Tamtam to see the decision-makers at Alnylam Pharmaceuticals, with verified emails and phone numbers, and find more companies like it.
See who to contact, freeAlnylam Pharmaceuticals account plan
Alnylam Pharmaceuticals is an RNAi biopharmaceutical company with six approved medicines, led by AMVUTTRA; about 2,500 employees.
Alnylam Pharmaceuticals in the news
- Alnylam invests $250m to boost RNAi manufacturing in the US
Alnylam is investing $250 million to expand its Massachusetts facility with an FDA-accepted enzymatic ligation platform to boost RNAi therapeutic manufacturing capacity and reduce costs.
- Alnylam Pharmaceuticals (ALNY) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025
Alnylam Pharmaceuticals is transitioning to a commercial-scale biotech with strong revenue growth from Amvuttra, Nasdaq-100 inclusion, UK reimbursement approval, manufacturing expansion, and ongoing federal scrutiny.
- Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by U.S. Capital Wealth Advisors LLC
Alnylam Pharmaceuticals saw notable insider and institutional stock sales amid generally positive analyst ratings, continuing its focus on RNAi therapeutics development.
Alnylam Pharmaceuticals at a glance
Alnylam Pharmaceuticals is a B2B company in the Biotechnology Research industry, headquartered in cambridge, massachusetts, United States.
Alnylam Pharmaceuticals was founded in 2002.
Alnylam Pharmaceuticals has 1,001–5,000 employees.
Alnylam Pharmaceuticals's revenue is €86.1M (FY2025, filed accounts, INPI).
Alnylam Pharmaceuticals's SIREN number is 818575730.
Frequently asked questions about Alnylam Pharmaceuticals
What is Alnylam Pharmaceuticals's revenue?
Alnylam Pharmaceuticals's revenue is €86.1M (FY2025, filed accounts, INPI).
How many employees does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 1,001–5,000 employees.
Where is Alnylam Pharmaceuticals headquartered?
Alnylam Pharmaceuticals is headquartered in cambridge, massachusetts, United States.
Selling to companies like Alnylam Pharmaceuticals?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies